TransCode also has three cancer agnostic programs—TTX-RIGA, an RNA–based agonist of the retinoic acid-inducible gene I (RIG-I)–driven immune response in the tumor microenvironment ...

Researchers at Cellectis leveraged gene editing to create a CAR T cell that acts in an IF/THEN system. Traditional methods to develop CAR T cells that use the patient’s cells introduce challenges ...

Oncolytic viruses are therapeutic agents used for in situ immunization in cancer immunotherapy. Unfortunately, its efficacy is particularly limited in solid tumors expressing stimulator of interferon ...